JP2019501133A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501133A5
JP2019501133A5 JP2018526682A JP2018526682A JP2019501133A5 JP 2019501133 A5 JP2019501133 A5 JP 2019501133A5 JP 2018526682 A JP2018526682 A JP 2018526682A JP 2018526682 A JP2018526682 A JP 2018526682A JP 2019501133 A5 JP2019501133 A5 JP 2019501133A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018526682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501133A (ja
JP6778747B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063254 external-priority patent/WO2017091544A1/en
Publication of JP2019501133A publication Critical patent/JP2019501133A/ja
Publication of JP2019501133A5 publication Critical patent/JP2019501133A5/ja
Application granted granted Critical
Publication of JP6778747B2 publication Critical patent/JP6778747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018526682A 2015-11-24 2016-11-22 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ Active JP6778747B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24
US62/259,273 2015-11-24
PCT/US2016/063254 WO2017091544A1 (en) 2015-11-24 2016-11-22 Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020141651A Division JP2020196742A (ja) 2015-11-24 2020-08-25 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ

Publications (3)

Publication Number Publication Date
JP2019501133A JP2019501133A (ja) 2019-01-17
JP2019501133A5 true JP2019501133A5 (enExample) 2019-11-14
JP6778747B2 JP6778747B2 (ja) 2020-11-04

Family

ID=57518004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526682A Active JP6778747B2 (ja) 2015-11-24 2016-11-22 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ
JP2020141651A Pending JP2020196742A (ja) 2015-11-24 2020-08-25 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020141651A Pending JP2020196742A (ja) 2015-11-24 2020-08-25 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ

Country Status (33)

Country Link
US (3) US10435428B2 (enExample)
EP (1) EP3380486B1 (enExample)
JP (2) JP6778747B2 (enExample)
KR (1) KR20180080330A (enExample)
CN (1) CN108290918B (enExample)
AU (1) AU2016359494B2 (enExample)
BR (1) BR112018010650A8 (enExample)
CA (1) CA3003283A1 (enExample)
CL (1) CL2018001345A1 (enExample)
CO (1) CO2018005327A2 (enExample)
CY (1) CY1122918T1 (enExample)
DK (1) DK3380486T3 (enExample)
EA (1) EA035816B1 (enExample)
ES (1) ES2784523T3 (enExample)
HR (1) HRP20200561T1 (enExample)
HU (1) HUE049775T2 (enExample)
IL (1) IL259076B (enExample)
LT (1) LT3380486T (enExample)
ME (1) ME03757B (enExample)
MX (1) MX383107B (enExample)
MY (1) MY189979A (enExample)
NZ (1) NZ742574A (enExample)
PH (1) PH12018501037A1 (enExample)
PL (1) PL3380486T3 (enExample)
PT (1) PT3380486T (enExample)
RS (1) RS60237B1 (enExample)
SG (1) SG11201803686UA (enExample)
SI (1) SI3380486T1 (enExample)
SM (1) SMT202000242T1 (enExample)
TW (1) TWI703147B (enExample)
UA (1) UA121270C2 (enExample)
WO (1) WO2017091544A1 (enExample)
ZA (1) ZA201802967B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
AU2016359494B2 (en) 2015-11-24 2021-01-07 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
BR112019024509A2 (pt) 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
US10233174B2 (en) * 2017-05-23 2019-03-19 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
WO2018226732A1 (en) * 2017-06-05 2018-12-13 Flagship Pioneering Innovations V, Inc. Multibiotic agents and methods of using the same
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
WO2019182322A1 (ko) * 2018-03-20 2019-09-26 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
EP3847158A1 (en) * 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
EP3880836A4 (en) * 2018-11-15 2022-11-16 Janssen Biotech, Inc. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO INFLAMMATORY BOWEL DISEASE THERAPY
PH12021551455A1 (en) * 2018-12-19 2022-04-18 Incyte Corp Jak1 pathway inhibitors for the treatment of gastrointestinal disease
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20210139857A1 (en) * 2019-11-13 2021-05-13 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230107927A1 (en) * 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2021231272A1 (en) * 2020-05-14 2021-11-18 Theravance Biopharma R&D Ip, Llc Administration of gut-selective jak3 inhibitor
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
WO2022087313A1 (en) * 2020-10-22 2022-04-28 Progenity, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
US20240307396A1 (en) * 2021-06-07 2024-09-19 The Regents Of The University Of California Compositions and methods for treating celiac disease
IL309840A (en) * 2021-07-20 2024-02-01 Coval Biopharma Shanghai Co Ltd An external antidialectic coupling compound drug, and a method of preparation therefor and use thereof
WO2023225463A2 (en) * 2022-05-14 2023-11-23 3-D Matrix, Ltd. Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
WO2024039599A1 (en) 2022-08-17 2024-02-22 Transcend Therapeutics, Inc. Phenethylamines and cathinones precursors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
CN105541847B (zh) 2009-10-09 2019-08-16 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
WO2011079249A2 (en) 2009-12-23 2011-06-30 Glycomyr, Inc. Use of vitamin d glycosides and sulfates for treatment of disease
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011097087A1 (en) * 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
AU2014273983A1 (en) 2013-05-31 2015-12-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for the therapeutic delivery
ES2742179T3 (es) * 2014-06-24 2020-02-13 Inst Nat Sante Rech Med Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino
AU2016359494B2 (en) 2015-11-24 2021-01-07 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
WO2017106957A1 (en) 2015-12-23 2017-06-29 The University Of British Columbia Lipid-linked prodrugs
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Similar Documents

Publication Publication Date Title
JP2019501133A5 (enExample)
KR102488479B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
JP6716785B2 (ja) Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物
CN107207498B (zh) 用于治疗hiv的稠合嘧啶化合物
JP2014511892A5 (enExample)
CA3163424A1 (en) Methods for treating sars cov-2 infections
JP2016534063A5 (enExample)
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
TW201927771A (zh) 可作為蛋白質調節劑之雜環醯胺及其使用方法
JP2012524056A5 (enExample)
JP2015511638A5 (enExample)
JP2017518334A5 (enExample)
KR20180021730A (ko) 티로신 키나제 억제제
JP2019500387A5 (enExample)
EA035746B1 (ru) Производные хиназолина, применяемые для лечения вич
JP2013518107A5 (enExample)
JP2013542261A5 (enExample)
JP2014511891A5 (enExample)
JP2013544846A5 (enExample)
JP2011529071A5 (enExample)
JP2016506962A5 (enExample)
US20220001015A1 (en) Lymphatic system-directing lipid prodrugs
JP2013510123A5 (enExample)
JP2014513110A5 (enExample)
JP2017526677A5 (enExample)